middle.news
Neuren’s DAYBUE Sales Rise 20% as Japan Trial Accelerates
10:22am on Thursday 7th of May, 2026 AEST
•
Pharmaceuticals
Read Story
Neuren’s DAYBUE Sales Rise 20% as Japan Trial Accelerates
10:22am on Thursday 7th of May, 2026 AEST
Key Points
Q1 2026 DAYBUE net sales up 20%
Royalties increase 23% to US$10.4 million
DAYBUE STIX powder gains strong caregiver approval
Japan trofinetide trial accelerated with topline data due Sep-Nov 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE